India's Largest Database on New Projects
Suven’s USFDA studies completed
19 May 2011: Suven Life Sciences’ (Suven) clinical drug candidate SUVN-502 has completed all the long-term chronic studies essential for US Food and Drug Authority (USFDA) to initiate human Phase-II clinical trials. SUVN-502 has been tested in human Phase 1 trials in Switzerland and demonstrated to be very safe at all doses and durations tested. The next stage will be proof of concept Phase II clinical trials in patients with Alzheimer's/Schizophrenia disease.
Source: Hindu Business Line